Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.55 |
| ▸ | ITGAV | P06756 | 8/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.49 |
| ▸ | ITGA5 | P08648 | 6/20 | 0.49 |
| ▸ | MDM4 | O15151 | 3/20 | 0.49 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.49 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.49 |
| ▸ | ITGB8 | P26012 | 2/20 | 0.49 |
| ▸ | ITGA8 | P53708 | 2/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.48 |
| ▸ | GPR139 | Q6DWJ6 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3835291 | 0.94 | ITGB3 (0.51) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL6779116 | 0.94 | ITGB3 (0.51) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL6778587 | 0.93 | ITGB3 (0.49) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL6776866 | 0.92 | ITGB3 (0.53) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL6779560 | 0.92 | ITGB3 (0.50) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL6772198 | 0.91 | GPR139 (0.53) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL6773766 | 0.91 | F7 (0.48) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL6776850 | 0.90 | ITGB3 (0.49) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL244261 | 0.90 | ITGB3 (0.50) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL6779336 | 0.90 | ITGB3 (0.49) | ITGB3ITGA2BITGAVITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | claimed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | claimed |
| CN-1201454-A | Meta-guanidino, ureido, thioureido or azacyclic aminobenzoic acid derivatives as integrin antagonists | SEARLE & CO (US) | 1998-12-09 | — | — | CN | claimed |
| EP-0850221-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1998-07-01 | — | — | EP | claimed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | claimed |
| US-20200199079-A1 | META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS PAN INTEGRIN ANTAGONISTS | UNIV SAINT LOUIS (US) | 2020-06-25 | — | — | US | disclosed |
| US-10577330-B2 | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | SAINT LOUIS UNIVERSITY (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190023663-A1 | META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS PAN INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY | 2019-01-24 | — | — | US | disclosed |
| US-10035778-B2 | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | SAINT LOUIS UNIVERSITY (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180072684-A1 | META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS PAN INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY | 2018-03-15 | — | — | US | disclosed |
| WO-2017117538-A1 | META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS PAN INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20120003229-A1 | MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | GENESTE HERVE (DE) | 2012-01-05 | — | — | US | disclosed |
| EP-1235595-A2 | INTEGRIN-MEDIATED DRUG TARGETING | Bayer Aktiengesellschaft (DE) | 2002-09-04 | — | — | EP | disclosed |
| EP-1227847-A2 | INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND ALPHAVBETA3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | BASF AKTIENGESELLSCHAFT (DE) | 2002-08-07 | — | — | EP | disclosed |
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-2001024827-A2 | INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αVβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-12 | — | — | WO | disclosed |
| WO-2001017563-A2 | INTEGRIN-MEDIATED DRUG TARGETING | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-15 | — | — | WO | disclosed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0850221-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577330-B2 | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | ITGA2, ITGAL, ITGA5 | ITGB3 17/4885ITGA2B 4/4885ITGAV 12/4885 |
| US-20190023663-A1 | META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS PAN INTEGRIN ANTAGONISTS | ITGA2, ITGAL, ITGA5 | ITGB3 17/4885ITGA2B 4/4885ITGAV 12/4885 |
| US-20200199079-A1 | META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS PAN INTEGRIN ANTAGONISTS | ITGA2, ITGAL, ITGA5 | ITGB3 17/4885ITGA2B 4/4885ITGAV 12/4885 |
| US-20120003229-A1 | MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | ITGB3, ITGAV, ITGB1 | ITGB3 1/4885ITGA2B 9/4885ITGAV 2/4885 |
| US-20180072684-A1 | META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS PAN INTEGRIN ANTAGONISTS | ITGA2, ITGAL, ITGA5 | ITGB3 17/4885ITGA2B 4/4885ITGAV 12/4885 |
| US-10035778-B2 | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | ITGA2, ITGAL, ITGA5 | ITGB3 17/4885ITGA2B 4/4885ITGAV 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.